腎康注射液對慢性腎炎患者治療前后血清炎性細胞因子水平的影響

唐新仿，王曉玉，王錦年

?

腎康注射液對慢性腎炎患者治療前后血清炎性細胞因子水平的影響

唐新仿，王曉玉，王錦年

[摘要]目的：探討腎康注射液對慢性腎炎患者治療前后血清IL-18，TNF-a和hs-CRP炎性細胞因子水平的影響。方法：應用酶聯法和生化法對32例慢性腎炎患者治療前后血清IL-18，TNF-a和hs-CRP水平進行檢測，并與32名正常健康人作比較。結果：慢性腎炎患者治療前血清IL-18，TNF-a和hs-CRP水平均顯著地高于正常人組(P<0.01),經腎康注射液治療1個月后與正常人比較差異仍有顯著性(P<0.05)，但與治療前比較有明顯下降(P<0.01)。血清IL-18水平與TNF-a和hs-CRP水平呈正相關(P<0.01)。結論：慢性腎炎的發生和發展可能與血清IL-18，TNF-a和hs-CRP水平升高有關，腎康注射液可改善患者的炎性狀態，促進疾病的康復。

[關鍵詞]慢性腎炎；腎康注射液；白細胞介素-18； 腫瘤壞死因子-a； 超敏C-反應蛋白

Effect of Shenkang injection on inflammatory cytokines levels after treatment of patients with chronic nephritisTANGXin-fang,WANGXiao-yu,WANGJin-nian．(DepartmentofNephrology，LianyungangEastHospital,Jiangsu222042,China)

【Abstract】Objective：To study the effect of Shenkang injection on inflammatory cytokines levels after treatment of patients with chronic nephritis.Methods:Serum IL-18,TNF-а (with EliSA),and serum hs-CRP(with Biochemistry) levels were measured both before and after treatment of 32 patients with chronic nephritis as well as 32 controls.Results:Before treatment,the serum IL-18,TNF-a and hs-CRP levels were significantly higher in the patients than those in the controls(P<0.01).After treatment for 1 month,the levels dropped markedly,but still remained significantly higher than those in the controls(P<0.05).Serum IL-18 levels were positively correlated with TNF-a and hs-CRP levels (P<0.01).Conclusion:The pathogenesis and development of chronic nephritis might be closely associated with the increased levels of IL-18,TNF-a and hs-CRP.Shenkang injection can improve the patient's inflammatory state and promote rehabilitation of the disease.

【Key words】Chronic nephritis; Shenkang injection; Interleukin-18; Tumor necrosis factor-a; High-sensitive C-reactive protein

腎康注射液近年來在臨床應用廣泛受到關注，文獻報道屢見不鮮[1]。IL-18,TNF-a,hs-CRP為重要的炎性細胞因子，對疾病的發生和發展有重要的臨床價值[2]。本文對腎康注射液治療慢性腎炎患者治療前后血清IL-18,TNF-a和hs-CRP水平的影響進行了探討，現報告如下。

1資料與方法

1.1一般資料患者組：32例，男22例，女10例，年齡35～51歲，平均年齡44.2歲。均為我院腎內科經臨床明確診斷(包括體征、B超及實驗室系列檢測項目)的慢性腎炎患者。排除其他慢性病，如糖尿病。所有受試者簽署知情同意書，研究方案經連云港市東方醫院倫理委員會通過。正常人組：32例，男20例，女12例，年齡38～55歲，平均年齡45.6歲。均為我院健康體檢中心經健康體檢合格的正常人，無慢性腎臟病史。

1．2治療方法患者均予優質低蛋白、低鹽、低脂、低磷飲食，控制血壓，保持內環境穩定。給予腎康注射液(西安世紀盛康藥業有限公司生產，規格：每支20 ml)80～100 ml加入250 ml10%葡萄糖注射液中靜脈滴注，連續治療1個月。(1)血清IL-18,TNF-a水平檢測：酶聯法。……